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Purpose
To describe the clinical presentation of inflammatory
arthritis associated with inflammatory bowel disease
(IBD) in children
Methods
Retrospective study conducted in 3 French pediatric cen-
tres. Children presenting with IBD associated with inflam-
matory arthritis were included.
Results
Nine children aged from 2.8 to 14.9 years presented with
a Crohn's disease associated with arthritis. Rheumatic dis-
ease occurred 25 to 41 months before the diagnosis of IBD
(3 children), 8 to 62 months after the diagnosis of IBD (4
children) or at the same time of IBD (2 children). In the
first three children, polyarticular form of juvenile idio-
pathic arthritis and Still's disease were initially diagnosed.
IBD was diagnosed 2 to 7 months after the initiation of
etanercept (2 children) and anakinra (1 child). Arthritis
developed in children who received corticosteroids, inflix-
imab, methotrexate and/or azathioprine because of IBD.
Patients presented with peripheral arthritis, involving
knees (7 children), ankles (5 children), and rarely hips,
fingers, elbows and shoulders. 12/18 relapse of arthritis
occurred at the same time as relapses of IBD. Abdominal
manifestations included diarrhea, anal abscess, abdomi-
nal pain, vomiting, and loss of weight. Mean C reactive
protein value and erythrocyte sedimentation rate were102
mg/L and 58 mm at onset of the disease respectively.
Discussion
IBD may be diagnosed several years after the occurrence of
arthritis and must be searched for in children presenting
with arthritis and abdominal involvement and/or weight
loss. IBD may develop in children who receive etanercept
while infliximab does not prevent the occurrence of
inflammatory arthritis.
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